Lv1
60 积分 2022-10-11 加入
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
1天前
已完结
Shifting gears with CAR T cells for autoimmune diseases
8个月前
已完结
Systemic sclerosis
9个月前
已完结
Pathogenesis of systemic sclerosis—current concept and emerging treatments
9个月前
已完结
Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)
9个月前
已完结
CAR T-cell therapy in autoimmune diseases
9个月前
已完结
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
1年前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
1年前
已完结
Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer
1年前
已完结
The IL-2A receptor pathway and its role in lymphocyte differentiation and function
1年前
已完结
皖公网安备34019202002308
